Marimed (MRMD) Price to Sales (2012 - 2026)

Marimed (MRMD) has reported Price to Sales for 15 consecutive years, with 0.67 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Sales fell 3.57% year-over-year to 0.67 in Q2 2026; TTM through Jun 2026 was 0.17, a 1.95% decrease from a year earlier, with the FY2025 full-year figure at 0.22, down 23.0% from the prior year.
• Price to Sales was 0.67 for Q2 2026 at Marimed, down from 0.71 in the prior quarter.
• Over five years, Price to Sales peaked at 7.83 in Q1 2022 and troughed at 0.67 in Q2 2026.
• A 5-year average of 2.66 and a median of 2.13 in 2024 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales declined 0.92% in 2023 and tumbled 64.14% in 2025, its largest moves.
• Over 5 years, Price to Sales stood at 3.43 in 2022, then retreated by 21.3% to 2.7 in 2023, then plunged by 56.47% to 1.18 in 2024, then declined by 27.03% to 0.86 in 2025, then decreased by 21.9% to 0.67 in 2026.
• The last three Price to Sales figures came in at 0.67 (Q2 2026), 0.71 (Q1 2026), and 0.86 (Q4 2025), per Business Quant data.